Indian Journal of Pharmacology Home 

RESEARCH ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2020  |  Volume : 52  |  Issue : 6  |  Page : 476--481

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital

Vadlakonda Sruthi, Resu Neha Reddy, K Sowmini, Nagur Sharone Grace 
 Department of Pharmacology, Osmania Medical College, Hyderabad, Telangana, India

Correspondence Address:
Dr. Resu Neha Reddy
Department of Pharmacology, Osmania Medical College, Turrebaz Road, Koti, Hyderabad - 500 095, Telangana
India

INTRODUCTION: Vernal conjunctivitis comprises 0.5% of allergic eye diseases. The study is intended to collate the effectiveness of drugs by observing the reduction in signs and symptoms. OBJECTIVES: The objective of the study is to evaluate the effectiveness and safety of olopatadine 0.1% ophthalmic drops with bepotastine besilate 1.5% ophthalmic drops in patients with vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: A randomized, open-label, comparative study conducted in Sarojini Devi Eye Hospital, Telangana. The study included 50 patients diagnosed with VKC, of which Group A and Group B were given olopatadine 0.1% ophthalmic drops and bepotastine besilate 1.5% ophthalmic drops, respectively, twice a day for 8 weeks. The reduction in signs and symptoms in both groups was compared. The observations and results were tabulated accordingly, and data were analyzed using the SPSS. The unpaired t-test is used as the test of significance in between two groups. P value is statistically significant when it is less than 0.05. RESULTS: Overall, 50 cases were included in the study, 72% of total patients were in the age group of 5–10 years, and 28% were in the age group of 11–15 years. There were 39 males and 11 females. After 8 weeks of follow-up, the mean reduction in the scoring of symptoms and signs provided better and quicker relief of watering, ocular discomfort, and conjunctival hyperemia with bepotastine 1.5% eye drops. Olopatadine 0.1% eye drops provided faster improvement in papillary hypertrophy. Both drugs were equally effective in reducing itching. Laboratory findings of absolute eosinophil count had no statistical significance in between the two groups. CONCLUSIONS: In this study, based on the evaluation of therapeutic performance, bepotastine eye drops proved quicker relief of symptoms and signs compared to olopatadine eye drops but was not statistically significant which would prove beneficial for the patients.


How to cite this article:
Sruthi V, Reddy RN, Sowmini K, Grace NS. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital.Indian J Pharmacol 2020;52:476-481


How to cite this URL:
Sruthi V, Reddy RN, Sowmini K, Grace NS. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian J Pharmacol [serial online] 2020 [cited 2021 Sep 18 ];52:476-481
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=6;spage=476;epage=481;aulast=Sruthi;type=0